Difference between revisions of "Cycloserine"

From Self-sufficiency
Jump to: navigation, search
m (Applications and side effects unrelated to antibiotic activity: d-4-amino-3-isoxazolidone)
 
m (1 revision: World Health Organization essential medicines)
 
(2 intermediate revisions by 2 users not shown)
Line 42: Line 42:
 
The side effects are mainly central nervous system (CNS) manifestations, i.e. [[headache]], irritability, [[depression (mood)|depression]], [[psychosis]] convulsions.  Co-administration of [[pyridoxine]] can reduce the incidence of some of the CNS side effects (e.g. convulsions).  
 
The side effects are mainly central nervous system (CNS) manifestations, i.e. [[headache]], irritability, [[depression (mood)|depression]], [[psychosis]] convulsions.  Co-administration of [[pyridoxine]] can reduce the incidence of some of the CNS side effects (e.g. convulsions).  
  
These psychotropic responses are related to D-cycloserine's action as a partial [[agonist]] of the neuronal [[NMDA receptor]] for [[glutamate]] and have been examined in implications with sensory-related fear [[extinction (psychology)|extinction]] in the [[amygdala]].<ref name="Davis" />
+
These psychotropic responses are related to D-cycloserine's action as a partial [[agonist]] of the neuronal [[NMDA receptor]] for [[glutamate]] and have been examined in implications with sensory-related fear [[extinction (psychology)|extinction]] in the [[amygdala]]<ref name="Davis" />, and [[extinction (psychology)|extinction]] of [[cocaine]] seeking in the [[nucleus accumbens]].<ref>{{cite web|url=http://www.eurekalert.org/pub_releases/2010-08/sfn-mdm073010.php|title=Memory-boosting drug may help cocaine addicts avoid relapse|date=2010-08-03}}</ref><!--- To appear in the August 4th issue at http://www.jneurosci.org/ --->
 +
 
 +
D-cycloserine is a [[partial agonist]] at the [[glycine receptor]], and has been shown to have cognition-enhancing properties for models of [[Parkinsons disease]] in [[primates]]. <ref>{{cite web|url=http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6SYR-3YTT0SF-W&_user=10&_coverDate=03/31/2000&_rdoc=1&_fmt=high&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=257ca54d8d673142fb6818807a695015|title=Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys|date=2000-17-03}}</ref>
  
 
== References ==
 
== References ==
Line 55: Line 57:
 
[[Category:Antibiotics]]
 
[[Category:Antibiotics]]
 
[[Category:World Health Organization essential medicines]]
 
[[Category:World Health Organization essential medicines]]
[[Category:Isoxazoles]]
 
 
[[Category:Lactams]]
 
[[Category:Lactams]]
 +
[[Category:Isoxazolidinones]]
  
 
[[de:Cycloserin]]
 
[[de:Cycloserin]]

Latest revision as of 15:44, 27 September 2010

Cycloserine
File:Cycloserine.svg
Systematic (IUPAC) name
(R)-4-amino-1,2-oxazolidin-3-one
Clinical data
Pregnancy
category
  • C
Pharmacokinetic data
Bioavailability ~70% to 90%
Metabolism Hepatic
Identifiers
CAS Number 68-41-7
ATC code J04AB01 (WHO)
PubChem CID 6234
DrugBank APRD00894
ChemSpider 5998
Chemical data
Formula C3H6N2O2
Molar mass 102.092 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Cycloserine is an antibiotic effective against Mycobacterium tuberculosis. For the treatment of tuberculosis, it is classified as a second line drug, i.e. its use is only considered if one or more first line drugs cannot be used.

Although in principle active against other bacteria as well, cycloserine is not commonly used in the treatment of infections other than tuberculosis.

Mode of action

The terminal two amino acid residues of the murein precursor lipid II consist of D-alanine, which is produced by the enzyme alanine racemase; the two residues are joined by D-alanine ligase. Both enzymes are competitively inhibited by cycloserine.[1]

Applications and side effects unrelated to antibiotic activity

It is also being trialed as an adjuvant to exposure therapy for anxiety disorders (e.g. phobias[2]), depression, obsessive-compulsive disorder and schizophrenia. It has been experimentally used for treatment of Gaucher's disease.

Recent research suggests that D-cycloserine (d-4-amino-3-isoxazolidone) may be effective in treating chronic pain.[3]

The side effects are mainly central nervous system (CNS) manifestations, i.e. headache, irritability, depression, psychosis convulsions. Co-administration of pyridoxine can reduce the incidence of some of the CNS side effects (e.g. convulsions).

These psychotropic responses are related to D-cycloserine's action as a partial agonist of the neuronal NMDA receptor for glutamate and have been examined in implications with sensory-related fear extinction in the amygdala[2], and extinction of cocaine seeking in the nucleus accumbens.[4]

D-cycloserine is a partial agonist at the glycine receptor, and has been shown to have cognition-enhancing properties for models of Parkinsons disease in primates. [5]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
de:Cycloserin

it:Cicloserina pl:Cykloseryna pt:Oxamicina ru:Циклосерин

sr:Cikloserin
  1. "Cell Envelope.1995". Retrieved 2008-11-08. 
  2. 2.0 2.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. "Newly Identified Drug Relieves Suffering". Science Daily. 2007-06-05. Retrieved 2008-07-15. 
  4. "Memory-boosting drug may help cocaine addicts avoid relapse". 2010-08-03. 
  5. "Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys". 2000-17-03.  Check date values in: |date= (help)